Monopar Therapeutics.
biopharmaceutical company
- Reports this week
- 0
- Active events
- 0
- Connections
- 23
What's happening
Earlier this month
One to three months ago
-
Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.Some support2 reports
-
Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.Some support5 reports2 developments inside
Gone quiet
No new reports in 90+ days-
Monopar Therapeutics submitted a New Drug Application (NDA) to the FDA for review.Some support1 report
-
The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.Some support1 report
-
Monopar Therapeutics shares began trading on the Nasdaq stock exchange.Well supported4 reports
-
Monopar Therapeutics held an ANA meeting in Baltimore on September 3, 2025.Some support1 report
No events began in the chosen period. Widen it, or reset.
Around Monopar Therapeutics this week
News at the entities that move Monopar Therapeutics most-
FDA StructuralUnicycive Therapeutics, Inc. is facing investigator findings regarding manufacturing compliance issues from the FDA.Moves Monopar Therapeutics
-
Manufacturers Life Insurance Company TransactionalManulife Insurance Company is utilizing Axiom to advance its global growth strategy.Moves Monopar Therapeutics
-
Cantor Fitzgerald Mentioned togetherThe event reports that Brooke Rollins serves as Trump's Agriculture Secretary and notes that Lutnick previously ran Cantor Fitzgerald.Moves Monopar Therapeutics
-
SEC StructuralStarton filed its S-1 registration statement and plans to list on the Nasdaq exchange.Moves Monopar Therapeutics
-
MarketBeat Mentioned togetherMarketBeat released analyst recommendations for small-cap communication services companies Optimum Communications and Criteo.Moves Monopar Therapeutics
-
Morgan Stanley Mentioned togetherAnthropic has submitted a confidential draft registration to the SEC, targeting an IPO debut led by a major firm.Moves Monopar Therapeutics
Connections
The 8 strongest of 23, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
Chandler Robinson Structural
Chandler Robinson serves as the CEO of Monopar Therapeutics and holds a 1.1% equity stake in the company.
-
FDA Structural
FDA formally regulates Monopar Therapeutics, granting designations and requiring compliance with federal regulations.
-
SEC Structural
Monopar Therapeutics is required to file disclosures with the SEC as part of regulatory compliance.
-
Manufacturers Life Insurance Company Transactional
A purchased a new position in company shares of B.
-
MarketBeat Mentioned together
MarketBeat publishes financial and analyst ratings concerning Monopar Therapeutics.
-
Cantor Fitzgerald Mentioned together
Cantor Fitzgerald provides research reports and ratings that influence Monopar Therapeutics.
-
Morgan Stanley Mentioned together
Morgan Stanley provides analyst ratings and price targets for Monopar Therapeutics.
-
Nasdaq Shared context
Monopar Therapeutics is listed and trades its shares on the Nasdaq stock exchange.
History
Events by the month they beganOctober 2026
1 eventJune 2026
5 events- Analyst ratings published on MarketBeat for Monopar Therapeutics, which trades on the Nasdaq stock exchange.
- Monopar Therapeutics, having taken over sponsorship of ALXN1840 from Alexion, is enrolling in clinical trials and must comply with federal regulations.
- The FDA granted Rare Pediatric Disease designation to Monopar Therapeutics.
- Monopar Therapeutics shares began trading on the Nasdaq stock exchange.
- Monopar Therapeutics held an ANA meeting in Baltimore on September 3, 2025.